 |
|
|
|
May 2001 Cover
|
|
New research suggests that an HIV-infected patient developed pancreatitis after receiving hydroxyurea in an antiretroviral regimen that also included didanosine. Researchers from St. Bartholomew's Hospital in London
present the case of a 26-year-old man who was treated with stavudine, didanosine, and nevirapine for 1.5 years, at which point his viral load increased and he was given hydroxyurea two times a day. However, the drug was stopped
after 42 days, when the patient reported pain in his upper abdomen, and all drugs were stopped three weeks later, after the patient's condition worsened. Researchers suggest that adding hydroxyurea to the original drug regimen
could have precipitated didanosine-induced pancreatitis.
Editor's Note: from Reuters Health Info Services
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
